Article

OASIS to J&J: Acuvue Oasys is infringement

Glendora, CA?OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.

Glendora, CA-OASIS Medical filed a lawsuit against Johnson & Johnson/Johnson & Johnson Vision Care Inc. (J&J) in the U.S. District Court in the Central District of California, alleging that the companies' use of the name OASYS infringes and dilutes OASIS Medical's trademark rights. Acuvue Oasys with Hydraclear Plus is a trademark of Johnson & Johnson Vision Care Inc. for its line of Acuvue contact lenses.

"Our company spent 18 years developing a reputation for itself under the name 'OASIS,' " said Norman Delgado, president of OASIS Medical. "J&J has adopted the same name for its new contact lenses, which, like OASIS' products, are designed for patients suffering from dry eye. Considering the impact this will have on our company, we believe that we must defend our trademarks and the use of them."

Introduced in August 2005, Acuvue Oasys with Hydraclear Plus is the first daily wear contact lens made from senofilcon A, a new silicone hydrogel material said to be 50% smoother than other silicone hydrogel lenses, according to the company.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI sets the stage for global ophthalmic innovation at Stanford Summit on July 23
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game (Part 2)
(Image credit: Ophthalmology Times) 50 years of ophthalmology: What changed the game? (Part 1)
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) The Residency Report: Clinical insights from the iStent infinite trial
(Image credit: Ophthalmology Times) ASCRS 2025: Amar Shah, MD, on why hyperosmolar tear film before and after cataract surgery matters
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
© 2025 MJH Life Sciences

All rights reserved.